Skip to content

Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone

Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00925457
Enrollment
1608
Registered
2009-06-22
Start date
2007-03-31
Completion date
2009-03-31
Last updated
2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmias, Cardiac

Keywords

Serious ventricular arrhythmia, Sudden cardiac death, Domperidone, Case-control study, Saskatchewan residents, Observational Study

Brief summary

The purpose of this retrospective observational study is to obtain information to confirm or contradict the results of prior studies on domperidone and sudden cardiac death. The population studied are the Saskatchewan residents who used domperidone or another type of medication known as a Proton Pump Inhibitor (PPI) between 1990 and 2005. Information will be collected from various sources including the Saskatchewan Health (SH) database and Cancer Registry.

Detailed description

The purpose of this population-based, observational study is to evaluate the combined risk of serious ventricular arrhythmia (irregular heart rhythm) and sudden cardiac death in users of domperidone (a medication used to treat certain gastrointestinal disorders) compared with users of proton pump inhibitors (another group of medications used to reduce gastric or stomach acid production. The study will be conducted using patient information from Saskatchewan Health (SH) who had recorded dispensings of domperidone or a PPI from 1990 through 2005. The first objective of the study is to estimate the combined relative risk of the occurrence of a particular type of irregular heart rhythm known as serious ventricular arrhythmia (SVA) and sudden cardiac death SCD (defined as a natural death from an unexpected circulatory arrest) during current use of domperidone or current use of proton pump inhibitors (PPIs) as compared with nonuse in a diabetic population. The second objective is to estimate the combined relative risk of SVA and SCD during current use of domperidone or current use of PPIs as compared with nonuse in a non-diabetic population. Study drug dosing information not required for Observational Study

Interventions

OTHERNo Intervention

Neither current domperidone nor current PPI

DRUGCurrent Domperidone

Current domperidone at any dose, regardless of proton pump inhibitor status

DRUGCurrent proton pump inhibitor (PPI)

Current PPI and not current dapoxetine

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 99 Years
Healthy volunteers
No

Inclusion criteria

* Saskachewan residents who received domperidone or a proton pump inhibitor (PPI) between January 1, 1990, and December 31, 2005

Exclusion criteria

* Cancer free \>=1 year of history in the database before receiving the first dose of domperidone or a PPI

Design outcomes

Primary

MeasureTime frame
The occurrence of serious ventricular arrhythmia and sudden cardiac death (combined end point)Retrospective study

Secondary

MeasureTime frame
The second objective is to estimate the combined relative risk of SVA and SCD during current use of domperidone or current use of PPIs as compared with nonuse in a non-diabetic population.Retrospective

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026